https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1112/2025111200239 _c.pdf 四川百利天恒药业股份有限公司 关于发行 H 股并上市的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）正在进行发行 H 股 股票并在香港联合交易所有限公司（以下简称"香港联交所"）主板挂牌上市（以 下简称"本次发行"）的相关工作。 2025 年 11 月 7 日，公司在香港联交所网站刊登并派发 H 股招股说明书及 H 股香港公开发售安排等事宜。具体内容详见公司 2025 年 11 月 7 日在上海证券交 易所官方网站（www.sse.com.cn）披露的《四川百利天恒药业股份有限公司关于 刊发 H 股招股说明书、H 股发行价格区间及 H 股香港公开发售等事宜的公告》 （公告编号：2025-082）。 鉴于目前的市场情况，公司决定延迟本次 H 股的全球发售及上市，并于 2025 年 11 月 12 日在香港联 ...

因本次拟发行的股份为H股，本次发行股份的认购对象仅限于符合相应条件的境外投资者及依据中国相 关法律法规有权进行境外证券投资管理的境内证券经营机构和合格境内机构投资者及其他符合监管规定 的投资者，公司将不会在境内证券交易所的网站和符合监管机构规定条件的媒体上刊登公告内容，相关 公告内容可于香港联交所网站进行查询。 智通财经APP讯，百利天恒(688506.SH)发布公告，鉴于目前的市场情况，公司决定延迟本次H股的全球 发售及上市，并于2025年11月12日在香港联交所网站发布公告。 ...

Core Viewpoint - Bailitianheng has gained significant attention in the capital market due to a 13-fold increase in stock price over two years, its status as the richest company on the Sci-Tech Innovation Board, and its innovative cancer drug, which is considered a breakthrough in the Chinese biopharmaceutical industry [1] Company Insights - The founder of Bailitianheng, Zhu Yi, has addressed both praise and skepticism from the public regarding the company's rapid growth and innovation [1] - The company aims to evolve into a multinational pharmaceutical enterprise originating from China, indicating its ambition for global expansion [1] Industry Context - The developments surrounding Bailitianheng are viewed as a gamble on innovative pharmaceuticals, reflecting broader trends and challenges within the Chinese biopharmaceutical sector [1] - The company is planning to establish a new strategic presence in Shanghai, which signifies its intent to further its market reach and operational capabilities [1]

Core Viewpoint - The global offering of Bailitianheng (2615.HK) has been delayed due to current market conditions, and the company will not proceed with the international underwriting agreement or unconditional public offering agreement [1] Group 1: Offering Details - Bailitianheng's public offering was initially scheduled from November 7 to November 12, with a planned listing on November 17 [1] - The company announced that application funds will be refunded on November 17, following the decision to delay the global offering [1] Group 2: Subscription and Demand - As of the morning of November 12, the estimated margin for Bailitianheng was approximately HKD 6.33 billion, indicating an oversubscription of about 17.8 times based on the public offering amount of HKD 336 million [1] Group 3: Business Impact - The company stated that the decision to delay the global offering does not affect its current business operations, and it remains committed to developing and expanding its business [1] - Bailitianheng and its overall coordinators are carefully assessing the timeline for the global offering and listing [1]

Core Viewpoint - The global offering of Bailitianheng (02615.HK) has been delayed due to current market conditions, and the company will not proceed with the initial public offering as planned [1] Group 1: Offering Details - Bailitianheng's public offering was initially scheduled from November 7 to 12, with a listing date of November 17 [1] - The company announced that the international underwriting agreement will not be established, and the public offering underwriting agreement will not become unconditional [1] - As of today, the estimated margin for Bailitianheng is approximately HKD 6.33 billion, with the public portion raising HKD 336 million, resulting in an oversubscription of about 17.8 times [1] Group 2: Business Impact - The decision to delay the global offering does not affect the company's current business operations, and the company remains committed to developing and expanding its business [1] - The company and its overall coordinators are carefully evaluating the updated timeline for the global offering and listing [1]

Core Insights - A-shares core assets showed strong performance, leading the Shanghai Composite Index to turn positive in early trading on November 12 [1] - Key sectors such as oil and gas extraction, insurance, banking, medical devices, and innovative pharmaceuticals saw significant gains [1] Market Performance - The CSI A500 Index experienced fluctuations in early trading, with the A500 ETF from E Fund (159361) recording a trading volume exceeding 1.7 billion yuan within the first hour, indicating increased activity compared to the previous day [1] - Leading stocks included Enjie Co., Ltd., XW Communications, and China Aluminum, contributing to the index's performance [1] Sector Analysis - The innovative pharmaceutical ETF from E Fund (516080) also saw a rise of over 1.7% in early trading, driven by strong performances from stocks like Baillie Tianheng, Zai Lab, and BeiGene [1] - Despite market adjustments, the Shanghai Composite Index remained above 4000 points, suggesting that the adjustments are within a healthy range [1] Investment Strategy - Analysts suggest that the frequent switching of market styles has increased operational difficulty for investors, recommending a focus on the A500 Index for a balanced investment approach [1] - The CSI A500 Index consists of 500 stocks with large market capitalization and good liquidity, optimizing industry balance and covering most of the CSI's tertiary industries [1] Cost Efficiency - The management fee for the A500 ETF from E Fund (159361) is only 0.15% per year, providing a low-cost option for investors to gain exposure to core A-share assets [1]

Group 1 - The core viewpoint of the articles highlights a strong performance in the innovative drug sector, with the Medical Innovation ETF (516820.SH) rising by 1.06% and key stocks like Sangfor Technologies (688336) and Baillie Gifford (688506) showing significant gains [1] - Over the past week, the Medical Innovation ETF has seen continuous net inflows, with a peak single-day net inflow of 44.28 million yuan, totaling 78.69 million yuan and an average daily net inflow of 11.24 million yuan [1] - Recent negotiations for the 2025 National Basic Medical Insurance Drug List and commercial insurance innovative drug pricing have been completed, with 120 domestic and foreign companies participating [1] Group 2 - The recent trend in innovative drug business development (BD) is accelerating, with overseas Phase III clinical trials progressing quickly, leading to a recovery in sentiment within the innovative drug sector [1] - The industry is witnessing a positive trend in investment and financing data, orders, and performance, indicating a recovery in the innovative drug supply chain [1] - The expectation of a rate cut in the U.S. is anticipated to enhance global liquidity and support the trend in technology stocks, providing an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF [2]

Core Insights - On November 11, brokerages issued target prices for listed companies a total of 21 times, with notable increases in target prices for Century Huatong, ZTE Corporation, and Zhuhai Smelter Group, showing increases of 50.48%, 47.02%, and 34.74% respectively, across the gaming, communication equipment, and industrial metals sectors [1][2]. Target Price Increases - Century Huatong received a target price of 26.50 yuan, reflecting a target price increase of 50.48% [2]. - ZTE Corporation's target price was set at 60.13 yuan, indicating a 47.02% increase [2]. - Zhuhai Smelter Group's target price reached 20.40 yuan, with a 34.74% increase [2]. - Other companies with significant target price increases include Jinlei Co. (30.79%), Changan Automobile (30.29%), and Sanhua Intelligent Control (29.84%) [2]. Brokerage Recommendations - The top companies recommended by brokerages on November 11 include Zhonglian Heavy Industry, Xinbao Co., and Sany Heavy Industry, each receiving two brokerage ratings [3]. - Zhonglian Heavy Industry had a closing price of 8.44 yuan, while Xinbao Co. closed at 15.30 yuan, and Sany Heavy Industry at 20.91 yuan [3]. Rating Adjustments - Nanjing Steel Group's rating was upgraded from "Hold" to "Buy" by Zhongtai Securities on November 11 [4]. - A total of 14 companies received first-time coverage from brokerages, with Zhejiang Energy Power rated "Hold" and Zhonggu Logistics rated "Hold" as well [5]. Newly Covered Companies - Newly covered companies include Zhejiang Energy Power (rated "Hold"), Zhonggu Logistics (rated "Hold"), and Longxin General (rated "Outperform") [5]. - Other companies receiving first-time ratings include Yifeng Pharmacy (rated "Outperform") and Haier Smart Home (rated "Buy") [5].

Core Viewpoint - The Hong Kong Stock Exchange welcomes another "A+H" biopharmaceutical company, Baillie Tianheng, which has launched its IPO with a price range of HKD 347.50 to HKD 389.00, despite facing significant financial challenges and a lack of sustainable revenue sources [2][4]. Financial Performance - In 2024, Baillie Tianheng is projected to generate revenue of CNY 58.23 billion and a net profit of CNY 37.08 billion, largely due to an $800 million upfront payment from a partnership with Bristol-Myers Squibb (BMS) [2]. - However, in the first half of 2025, the company's revenue is expected to plummet to CNY 1.71 billion, a staggering decline of 96.92% year-on-year, with a net loss of CNY 11.18 billion [2]. - The company's R&D expenses reached CNY 10.39 billion in the first half of 2025, a 90.74% increase, amounting to approximately six times its revenue during the same period [2]. Product Pipeline - Baillie Tianheng's core product, iza-bren, is the world's first EGFR×HER3 dual-targeted ADC drug and the only one in Phase III clinical development, with a total licensing agreement worth up to $8.4 billion with BMS [4]. - Clinical data presented at the 2025 European Society for Medical Oncology meeting showed an overall objective response rate of 55% in patients with advanced heavily pre-treated solid tumors, indicating its potential as a broad-spectrum drug [5]. - Another promising drug, T-Bren, demonstrated an objective response rate of 82.2% in HER2-positive breast cancer patients, with a median progression-free survival of 18 months, showcasing better therapeutic potential compared to its competitor [6]. Market Dynamics - The IPO has attracted five cornerstone investors, including BMS and Athos Capital, who collectively subscribed to approximately HKD 248 million worth of shares, representing 7.8% of the offering [7]. - The absence of a greenshoe option in the IPO raises concerns about price stability post-listing, especially given the recent underperformance of A+H shares in the biopharmaceutical sector [8]. - The high entry cost of HKD 39,292.31 for retail investors may deter participation, suggesting a cautious approach for those less familiar with the biopharmaceutical industry [8].

Core Viewpoint - The recent IPO of BaiLi Tianheng in the Hong Kong market is expected to fill a gap in the ADC drug sector, driven by technological advancements, surging demand, and supportive policies [1][2]. Group 1: IPO Details - BaiLi Tianheng plans to launch its H-share global public offering with a base issuance of 8,634,300 shares, including 863,500 shares for public sale in Hong Kong [1]. - The price range for the shares is set between 347.50 HKD and 389.00 HKD, with trading expected to commence on November 17 [1]. - The H-shares are eligible for inclusion in the Stock Connect program on the listing date [1]. Group 2: Strategic Partnerships and Market Position - The IPO has attracted significant interest from major investors, including Goldman Sachs, JPMorgan, and notable cornerstone investors like Bristol-Myers Squibb (BMS) [2][3]. - BaiLi Tianheng's strong market position is attributed to its robust ADC drug development, independent global clinical capabilities, and innovative commercialization strategies [2]. - The partnership with BMS involves a groundbreaking deal worth 8.4 billion USD for the ADC product Iza-bren, marking a significant milestone in the ADC sector [3][4]. Group 3: Product Development and Clinical Trials - Iza-bren is the first-in-class dual-target ADC drug, currently in Phase III clinical trials, showing promising efficacy with a 55% overall response rate in late-stage cancer patients [5][6]. - The drug's potential peak sales could exceed 20 billion USD, indicating a strong commercial outlook [5][6]. - BaiLi Tianheng is also advancing another ADC, T-Bren, which has shown superior efficacy and safety compared to competitors, with a clinical objective response rate of 82.2% [7][8]. Group 4: Financial Strength and Future Prospects - As of June 30, BaiLi Tianheng had over 5 billion CNY in cash reserves, bolstered by a recent 3.764 billion CNY A-share placement and potential future payments from BMS [12]. - The company is positioned for significant growth in the global market, with a focus on building a comprehensive R&D and commercialization framework [10][11]. - The overall market sentiment towards innovative biopharmaceuticals is improving, with BaiLi Tianheng expected to be a key player in the sector [13].